Replimune Group Faces Class Action Lawsuit for Securities Violations: What Investors Should Know#USA#Los_Angeles#DJS_Law_Group#Biologics_License_Application#Replimune_Group
Replimune Group Faces Class Action Lawsuit for Securities Violations: What Investors Should Know
Investors of Replimune Group, Inc. might be eligible to participate in a class action lawsuit alleging securities law violations. Discover the details.
third-news.com
August 27, 2026 at 8:22 AM
Replimune Group Faces Class Action Lawsuit for Securities Violations: What Investors Should Know#USA#Los_Angeles#DJS_Law_Group#Biologics_License_Application#Replimune_Group
Pomerantz Law Firm's Investigation into Capricor Therapeutics: A Call to Investors#USA#New_York#Pomerantz_LLP#Biologics_License_Application#Capricor_Therapeutics
Pomerantz Law Firm's Investigation into Capricor Therapeutics: A Call to Investors
Pomerantz LLP is probing potential securities fraud by Capricor Therapeutics and urges investors to take action in light of recent stock price drops.
third-news.com
June 27, 2025 at 9:13 PM
Pomerantz Law Firm's Investigation into Capricor Therapeutics: A Call to Investors#USA#New_York#Pomerantz_LLP#Biologics_License_Application#Capricor_Therapeutics
VGXI Achieves Key FDA Inspection Success, Boosting Plasmid DNA Manufacturing Leadership#USA#Plasmid_DNA#VGXI_Inc#Biologics_License_Application#Conroe
VGXI Achieves Key FDA Inspection Success, Boosting Plasmid DNA Manufacturing Leadership
VGXI, a leader in plasmid DNA biopharmaceuticals, marks a significant achievement with FDA approval for a client's BLA following a successful inspection.
third-news.com
May 12, 2025 at 3:08 PM
VGXI Achieves Key FDA Inspection Success, Boosting Plasmid DNA Manufacturing Leadership#USA#Plasmid_DNA#VGXI_Inc#Biologics_License_Application#Conroe